TWI583383B - 治療高血壓之醫藥組成物及方法 - Google Patents

治療高血壓之醫藥組成物及方法 Download PDF

Info

Publication number
TWI583383B
TWI583383B TW100115056A TW100115056A TWI583383B TW I583383 B TWI583383 B TW I583383B TW 100115056 A TW100115056 A TW 100115056A TW 100115056 A TW100115056 A TW 100115056A TW I583383 B TWI583383 B TW I583383B
Authority
TW
Taiwan
Prior art keywords
amlodipine
pharmaceutical composition
dextromethorphan
hypertension
blood pressure
Prior art date
Application number
TW100115056A
Other languages
English (en)
Chinese (zh)
Other versions
TW201206437A (en
Inventor
陳肇文
王錫傑
莊欣怡
Original Assignee
東生華製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 東生華製藥股份有限公司 filed Critical 東生華製藥股份有限公司
Publication of TW201206437A publication Critical patent/TW201206437A/zh
Application granted granted Critical
Publication of TWI583383B publication Critical patent/TWI583383B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW100115056A 2010-05-03 2011-04-29 治療高血壓之醫藥組成物及方法 TWI583383B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33054010P 2010-05-03 2010-05-03

Publications (2)

Publication Number Publication Date
TW201206437A TW201206437A (en) 2012-02-16
TWI583383B true TWI583383B (zh) 2017-05-21

Family

ID=44903590

Family Applications (1)

Application Number Title Priority Date Filing Date
TW100115056A TWI583383B (zh) 2010-05-03 2011-04-29 治療高血壓之醫藥組成物及方法

Country Status (11)

Country Link
US (2) US20130053411A1 (enExample)
EP (1) EP2566478A4 (enExample)
JP (1) JP5847162B2 (enExample)
KR (1) KR20130061148A (enExample)
CN (1) CN102869360B (enExample)
AU (1) AU2011250485B2 (enExample)
BR (1) BR112012028153A2 (enExample)
MY (1) MY161853A (enExample)
RU (1) RU2571284C2 (enExample)
TW (1) TWI583383B (enExample)
WO (1) WO2011137734A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014126972A1 (en) * 2013-02-14 2014-08-21 Novartis Ag Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
TW201717947A (zh) * 2015-08-20 2017-06-01 漢達生技醫藥股份有限公司 包含氨氯地平和右美沙芬的藥物組合物
EP3554507A1 (en) 2016-12-14 2019-10-23 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
HRP20230267T1 (hr) 2017-01-25 2023-06-09 The George Institute for Global Health Pripravci za liječenje hipertenzije
US12521380B2 (en) 2017-01-25 2026-01-13 The George Institute for Global Health Compositions for the treatment of hypertension

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097608A2 (en) * 2002-05-17 2003-11-27 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2676177A (en) 1949-11-09 1954-04-20 Hoffmann La Roche Process for the preparation of optically active 3-methoxy-n-methyl morphinans and salts thereof
GB8710493D0 (en) 1987-05-02 1987-06-03 Pfizer Ltd Dihydropyridines
EP0557290A1 (en) * 1990-08-23 1993-09-01 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss
JPH04368338A (ja) * 1991-06-12 1992-12-21 Taisho Pharmaceut Co Ltd 鎮咳剤
US5350756A (en) * 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
US5560913A (en) 1995-01-27 1996-10-01 The Procter & Gamble Company Pharmaceutical compositions
CA2483306A1 (en) 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
KR100476636B1 (ko) 2002-09-11 2005-03-17 한림제약(주) 엘-(+)-타르트레이트를 이용한 에스-(-)-암로디핀의 제조방법
TWI313598B (en) * 2002-12-18 2009-08-21 Wyeth Corp Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
WO2006033965A2 (en) * 2004-09-16 2006-03-30 The Trustees Of The University Of Pennsylvania Nadph oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities
US20060188450A1 (en) * 2005-02-24 2006-08-24 Tim Clarot System and method for suppressing a cough
US7939567B2 (en) * 2006-02-24 2011-05-10 Blue Blood Biotech Corp. Dextromethorphan-based method for treating acne
US7820689B2 (en) * 2006-08-10 2010-10-26 Hua-Lin Wu Methods and compositions for preventing or treating cardiovascular disease
JP5745855B2 (ja) * 2007-11-28 2015-07-08 セコイア、ファーマシューティカルズ、インコーポレイテッドＳｅｑｕｏｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． シトクロムｐ４５０ ２ｄ６を阻害するための組成物および方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097608A2 (en) * 2002-05-17 2003-11-27 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Renin-Angiotensin-Aldosterone System, 2008, vol 9(1), 1-9. *

Also Published As

Publication number Publication date
KR20130061148A (ko) 2013-06-10
TW201206437A (en) 2012-02-16
CN102869360B (zh) 2015-03-25
EP2566478A1 (en) 2013-03-13
MY161853A (en) 2017-05-15
AU2011250485A1 (en) 2012-12-06
RU2012151051A (ru) 2014-06-10
US20160235741A1 (en) 2016-08-18
JP2013525460A (ja) 2013-06-20
WO2011137734A1 (en) 2011-11-10
CN102869360A (zh) 2013-01-09
RU2571284C2 (ru) 2015-12-20
JP5847162B2 (ja) 2016-01-20
US9744165B2 (en) 2017-08-29
BR112012028153A2 (pt) 2018-08-07
AU2011250485B2 (en) 2016-07-07
US20130053411A1 (en) 2013-02-28
EP2566478A4 (en) 2014-04-30

Similar Documents

Publication Publication Date Title
US9744165B2 (en) Method for treating hypertension
EP1096932B1 (en) Antihypertensive combination of valsartan and calcium channel blocker
US6395728B2 (en) Method of treatment and pharmaceutical composition
US20050203130A1 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US6204281B1 (en) Method of treatment and pharmaceutical composition
HUT77315A (hu) Loratadinszármazék allergiás és egyéb betegségek kezelésében való alkalmazásra
AU2009313906A1 (en) Treatment of proteinopathies using a farnesyl transferase inhibitor
CN107567444A (zh) 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物
TW200838510A (en) A preventive and/or therapeutical agent of hyperlipemia
AU2022387121A1 (en) Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders
CA2004616A1 (en) Therapeutic use of calcium entry blockers in retinal or optic nerve dysfunction
EP4491223A2 (en) Compound for use in the treatment of neurogenic orthostatic hypotension
US12582648B2 (en) Method for treating central nervous system disorders using dopamine D3 partial agonists
Guarneri et al. In vitro and in vivo vascular selectivity of lercanidipine and its enantiomers
JP2012532855A (ja) 医薬として使用するための組合せ製剤
JPS61155327A (ja) ジヒドロピリジン化合物を含有する抗動脈硬化剤
JP5441052B2 (ja) アルツハイマー病治療薬
JPH11335278A (ja) ドフェチリドおよびカルシウムチャネル遮断薬の組合わせ
CN101415425B (zh) 甘油三酯降低剂和高胰岛素血症改善剂
Kondo et al. The discovery of Samsca®(Tolvaptan): the first oral nonpeptide vasopressin receptor antagonist
WO2011000562A1 (en) Eltoprazine for the treatment of certain movement disorders
ITRM20100230A1 (it) Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
BR122025010953A2 (pt) Compostos de d-anfetamina, composição que compreende os mesmos, kit que compreende a dita composição e uso terapêutico dos ditos compostos
MXPA99004460A (en) Combination of dofetilida and a blocking of the calculates
WO2011000564A1 (en) Eltoprazine for the treatment of drug addiction

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees